Characterization of the inflammatory response to severe COVID-19 illness
Semaglutide currently has stronger evidence for heart health, making it the preferred option for patients with existing cardiovascular disease
Removing it reduces IGFBP affinity by approximately 90%, increasing the free fraction of the peptide available for IGF1R engagement
This guide is meant to help you compare options and, together with a licensed healthcare provider, decide what may be the best fit for you
Research on GLP-1-based therapies has shown that throat issues are connected to dehydration or reflux
We offer prescribed doses to be administered through self-injection once a week, along with the option to steadily titrate up, or increase dose, over time